
Yesterday, Entrada Therapeutics announced the latest progress in its ELEVATE-45-201 clinical trial, which is evaluating the safety and effectiveness of ENTR-601-45 in ambulatory children and young adults living with Duchenne muscular dystrophy who are eligible for exon 45 skipping. An independent safety Data Monitoring Committee (DMC) reviewed available data from the study’s second group of participants, which included eight people receiving a 10 mg/kg dose, and recommended moving forward with a higher 15 mg/kg dose for the third group.
After completing the study, participants will have the option to join a long-term extension study, allowing researchers to continue monitoring the treatment’s safety and potential benefits.
For more information, read Entrada’s latest community update.